Latest Headlines

  1. Arcturis And Royal Berkshire NHS Foundation Trust Enter Strategic Partnership 11/5/2025

    Arcturis, the UK leader in the curation of deep, multi-modal data to support the development of precision medicines, announces the continuing expansion of its Real-World Data Network (”RWD Network”) through the signing of a multi-year strategic partnership with Royal Berkshire NHS Foundation Trust (“Royal Berkshire”).

  2. NanoTemper Strengthens Biopharma Discovery Portfolio With Acquisition Of Envue Technologies And Launch of Dianthus™ α 11/5/2025

    NanoTemper Technologies, a leading provider of high-precision biophysical analysis tools, today announced its acquisition of Envue Technologies, a Swedish startup pioneering Nanofluidic Scattering Microscopy (NSM).

  3. Tenpoint Therapeutics Ltd. Announces Submission Of A New Drug Application For BRIMOCHOL PF For The Treatment Of Presbyopia To The MFDS In South Korea 11/5/2025

    Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that its partner, Zhaoke Ophthalmology Ltd. (“Zhaoke Ophthalmology”), a leading ophthalmic pharmaceutical company, has supported its South Korean partner, Kwangdong Pharmaceutical Co., Ltd. (“KDP”), in submitting a New Drug Application (NDA) for BRIMOCHOL PF to the Ministry of Food and Drug Safety (MFDS) in South Korea. KDP will be responsible for the manufacturing and distribution of BRIMOCHOL PF in South Korea.

  4. U.S. FDA Grants Orphan Drug Designation To Leukogene Therapeutics' M2T-CD33 (LTI-214) For The Treatment Of Acute Myeloid Leukemia 11/5/2025

    Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s lead product candidate, M2T-CD33 (LTI-214), for the treatment of Acute Myeloid Leukemia (AML).

  5. Sanyou Bio And Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement On Automated Development Of Innovative Biologics To Jointly Tackle R&D Bottlenecks And Provide New Momentum For Innovative Drug R&D 11/3/2025

    Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agreement on the automated development of innovative biologics. 

  6. IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline 11/3/2025

    IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced an expansion of its AI-powered in-Silico drug discovery platform.

  7. Nuclera Expands Access To eProtein Discovery For APAC Customers With Distributor Agreement In Australia And New Zealand 11/3/2025

    Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, today announced that it has signed a partnership with Solve Scientific Australia, a life science research solutions provider.

  8. Manifold Bio Announces Strategic Collaboration With Roche To Develop Multiple Next-Generation Brain Shuttles For Neurological Diseases 11/3/2025

    Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche.

  9. Debiopharm Forges AI-powered Alliance With NetTargets To Pioneer Dual-Payload ADCs Against Drug-Resistant Cancers 10/30/2025

    Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs).

  10. Foundation Medicine And Manifold Partner To Accelerate Drug Discovery And Development By Bringing AI-Enabled Analytics To FoundationInsights 10/30/2025

    Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced a partnership with Manifold, the leading artificial intelligence (AI) data platform for life sciences, to bring enhanced AI capabilities to FoundationInsights, a cloud-based data analytics and visualization platform that derives insights from Foundation Medicine’s proprietary multimodal datasets.